Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 877-883

  Zang, Dae Young ^a,b   Yang, Dae Hyun ^a   Kim, Min Jeong ^a   Jang, Kyung Mi ^a   Hwang, Se Won ^a   Yoo, Kyo Sang ^a   Han, Taeho ^a   Kim, Ho Young ^a   Kim, Hyo Jung ^a   Kwon, Jung Hye ^a   Song, Hun Ho ^a   Park, Sarah ^a   Jung, Joo Young ^a   Kim, Hyeong Su ^a   Kim, Jung Han ^a  

^a Hallym University Medical Center   (South Korea)

^b Hallym University Sacred Heart Hospital   (South Korea)

Author keywords

Docetaxel; Oxaliplatin; S1 (combination); Stomach neoplasm

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOCETAXEL; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR;

EID: 69049119139     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0936-6     Document Type: Article

References (23)

1. MS Aapro DA Cameron R Pettengell J Bohlius J Crawford M Ellis N Kearney GH Lyman VC Tjan-Heijnen J Walewski DC Weber C Zielinski European Organisation for Research, Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party 2006 EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2433 2453
2. JA Ajani FC Lee DA Singh DG Haller HJ Lenz AB Benson 3rd R Yanagihara AT Phan JC Yao D Strumberg 2006 Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma J Clin Oncol 24 663 667
3. SE Al-Batran JT Hartmann S Probst H Schmalenberg S Hollerbach R Hofheinz V Rethwisch G Seipelt N Homann G Wilhelm G Schuch J Stoehlmacher HG Derigs S Hegewisch-Becker J Grossmann C Pauligk A Atmaca C Bokemeyer A Knuth E Jäger 2008 Arbeitsgemeinschaft Internistische Onkologie Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 26 1435 1442
4. YJ Bang WK Kang YK Kang HC Kim C Jacques E Zuber B Daglish Y Boudraa WS Kim DS Heo NK Kim 2002 Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial Jpn J Clin Oncol 32 248 254
5. J Cassidy JL Misset 2002 Oxaliplatin-related side effects: characteristics and management Semin Oncol 29 11 20
6. D Cunningham N Starling S Rao T Iveson M Nicolson F Coxon G Middleton F Daniel J Oates AR Norman 2008 Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36 46
7. A Grothey 2003 Oxaliplatin-safety profile: neurotoxicity Semin Oncol 4 Suppl 15 5 13
8. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative gastric cancer study group Oncology 58 191 197
9. W Koizumi H Narahara T Hara A Takagane T Akiya M Takagi K Miyashita T Nishizaki O Kobayashi W Takiyama Y Toh T Nagaie S Takagi Y Yamamura K Yanaoka H Orita M Takeuchi 2008 S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215 221
10. F Lordick S Lorenzen J Stollfuss U Vehling-Kaiser F Kullmann M Hentrich R Zumschlinge H Dietzfelbinger J Thoedtmann M Hennig T Seroneit R Bredenkamp J Duyster C Peschel 2005 Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer Br J Cancer 93 190 194
11. C Louvet T André JM Tigaud E Gamelin JY Douillard R Brunet E François JH Jacob D Levoir A Taamma P Rougier E Cvitkovic A de Gramont 2002 Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 4543 4548
12. F Maindrault-Gœbell C Tournigand T André E Carola M Mabro P Artru C Louvet A de Gramont 2004 Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer Ann Oncol 15 1210 1214
13. D Mavroudis C Kourousis N Androulakis K Kalbakis S Agelaki S Kakolyris J Souglakos E Sarra N Vardakis D Hatzidaki G Sarmonis V Georgoulias 2000 Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial Am J Clin Oncol 23 341 344
14. K Ridwelski T Gebauer J Fahlke H Kröning E Kettner F Meyer K Eichelmann H Lippert 2001 Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer Ann Oncol 12 47 51
15. AD Roth N Fazio R Stupp S Falk J Bernhard P Saletti D Köberle MM Borner K Rufibach R Maibach M Wernli M Leslie R Glynne-Jones L Widmer M Seymour F de Braud 2007 Swiss Group for Clinical Cancer Research Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research J Clin Oncol 25 3217 3223
16. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720
17. TJ Smith J Khatcheressian GH Lyman H Ozer JO Armitage L Balducci CL Bennett SB Cantor J Crawford SJ Cross G Demetri CE Desch PA Pizzo CA Schiffer L Schwartzberg MR Somerfield G Somlo JC Wade JL Wade RJ Winn AJ Wozniak AC Wolff 2006 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187 3205
18. A Sulkes J Smyth C Sessa LY Dirix JB Vermorken S Kaye J Wanders H Franklin N LeBail J Verweij 1994 Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial EORTC early clinical trials group Br J Cancer 70 380 383
19. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216
20. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi ML Risse JA Ajani 2006 V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991 4997
21. K Yamaguchi T Shimamura I Hyodo W Koizumi T Doi H Narahara Y Komatsu T Kato S Saitoh T Akiya M Munakata Y Miyata Y Maeda H Takiuchi S Nakano T Esaki F Kinjo Y Sakata 2006 Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer Br J Cancer 94 1803 1808
22. K Yoshida M Ninomiya N Takakura N Hirabayashi W Takiyama Y Sato S Todo M Terashima M Gotoh J Sakamoto M Nishiyama 2006 Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402 3407
23. DY Zang DH Yang HW Lee SW Hwang HH Song JY Jung JH Kwon HJ Kim JH Kim SR Park M Kim KM Jang CK Park JH Kim BH Lee 2009 Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age Cancer Chemother Pharmacol 63 509 516